Impact Biomedical (IBO) Gross Margin (2025 - 2026)
Impact Biomedical's (IBO) quarterly Gross Margin came in at 66.67% in Q2 2026, down 1905.0% on a YoY basis from 3.69% in Q2 2025, and down 29.41% quarter-over-quarter from 94.44% in Q3 2025.
Powered by 
Analysis
Impact Biomedical (IBO) Gross Margin (2025 - 2026) Analysis & Trends
Impact Biomedical (IBO) has reported Gross Margin for 2 consecutive years, with 66.67% the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 80.31% |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 | 66.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66.67% |
| Sep 30, 2025 | 94.44% |
| Jun 30, 2025 | 85.71% |